Second surgery for recurrent ovarian cancer that responds to platinum
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer (the epithelial type).
- Your cancer came back at least 6 months after your last platinum chemotherapy session.
- You have had at least 3 rounds of platinum chemo (maybe with other drugs like Avastin or a PARP inhibitor).
- Doctors have said that a first surgery to remove all visible cancer was not possible.
- You feel well enough to have surgery (ECOG score 0–2).
- Your blood counts, kidney, liver, and nerve function are in a good range for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial tests whether a second surgery to remove all visible cancer can help people with ovarian cancer that came back within 6 months of finishing platinum chemotherapy. The goal is to see if this surgery improves outcomes compared with standard care.
This trial tests whether removing recurrent ovarian cancer with surgery after chemotherapy can help patients live longer. It is for women whose cancer came back at least 6 months after finishing platinum-based chemo and who responded to chemo after the recurrence.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
Hear when a new Recurrent Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.